Gene Test Shows Which Triple-Negative Breast Cancers Do Not Need Pre-Op Pembrolizumab Oncology Times - OncTimes Talk podcast

Artwork

Medicine Oncology Cancer Oncology Times Science News Health and Well-Being

Contenido proporcionado por Oncology Times. Todo el contenido del podcast, incluidos episodios, gráficos y descripciones de podcast, lo carga y proporciona directamente Oncology Times o su socio de plataforma de podcast. Si cree que alguien está utilizando su trabajo protegido por derechos de autor sin su permiso, puede seguir el proceso descrito aquí https://es.player.fm/legal.

Oncology Times - OncTimes Talk « »
Gene Test Shows Which Triple-Negative Breast Cancers Do Not Need Pre-Op Pembrolizumab

8M ago 15:44

Compartir

Contenido proporcionado por Oncology Times. Todo el contenido del podcast, incluidos episodios, gráficos y descripciones de podcast, lo carga y proporciona directamente Oncology Times o su socio de plataforma de podcast. Si cree que alguien está utilizando su trabajo protegido por derechos de autor sin su permiso, puede seguir el proceso descrito aquí https://es.player.fm/legal.

About a quarter of all patients with newly diagnosed triple-negative breast cancer will not benefit from neoadjuvant checkpoint inhibitor immunotherapy with an agent such as pembrolizumab—even though it improves outcomes among the remaining majority.

At the 14th European Breast Cancer Conference, held in Milan, Italy, Laura van ’t Veer, PhD, Program Leader of the Breast Oncology Program at the UCSF Helen Diller Family Comprehensive Cancer Center, reported findings from the I-SPY2 TRIAL showing that analysis of “response predictive subtypes” identified a subset of patients with triple-negative early-stage breast cancers with a very low likelihood of response to neoadjuvant immunotherapy and can be spared potential toxicities.

After her talk in Milan, van ’t Veer called in to the OncTimesTalk studio to talk about the I-SPY findings with Peter Goodwin.

… continue reading

174 episodios

#Medicine #Oncology #Cancer #Oncology Times #Science #News #Health and Well-Being

Artwork

Gene Test Shows Which Triple-Negative Breast Cancers Do Not Need Pre-Op Pembrolizumab

Oncology Times - OncTimes Talk

22 subscribers

published 8M ago

Compartir

Contenido proporcionado por Oncology Times. Todo el contenido del podcast, incluidos episodios, gráficos y descripciones de podcast, lo carga y proporciona directamente Oncology Times o su socio de plataforma de podcast. Si cree que alguien está utilizando su trabajo protegido por derechos de autor sin su permiso, puede seguir el proceso descrito aquí https://es.player.fm/legal.

About a quarter of all patients with newly diagnosed triple-negative breast cancer will not benefit from neoadjuvant checkpoint inhibitor immunotherapy with an agent such as pembrolizumab—even though it improves outcomes among the remaining majority.

At the 14th European Breast Cancer Conference, held in Milan, Italy, Laura van ’t Veer, PhD, Program Leader of the Breast Oncology Program at the UCSF Helen Diller Family Comprehensive Cancer Center, reported findings from the I-SPY2 TRIAL showing that analysis of “response predictive subtypes” identified a subset of patients with triple-negative early-stage breast cancers with a very low likelihood of response to neoadjuvant immunotherapy and can be spared potential toxicities.

After her talk in Milan, van ’t Veer called in to the OncTimesTalk studio to talk about the I-SPY findings with Peter Goodwin.

… continue reading

174 episodios

#Medicine #Oncology #Cancer #Oncology Times #Science #News #Health and Well-Being

Todos los episodios

×

Bienvenido a Player FM!

Player FM está escaneando la web en busca de podcasts de alta calidad para que los disfrutes en este momento. Es la mejor aplicación de podcast y funciona en Android, iPhone y la web. Regístrate para sincronizar suscripciones a través de dispositivos.

Escucha más de 500 temas